The companies plan to offer a service called MyMap, which will include MyGenome next-generation sequencing by Veritas and MediMap pharmacogenomic testing by Inova.
PerkinElmer Genetics will provide clinical whole-genome sequencing, data interpretation, and diagnostic reports to IDG for patients with neurological disorders.
The integration could provide a more complete phenotypic picture that helps clinicians prioritize genetic variants that may have otherwise been missed.
The two firms are offering a combined genetic disease risk and pharmacogenomic analysis that covers 49 conditions and about 220 medications.
SOL will help Personal Genomics to further develop its research projects and implement its new facility dedicated to DNA sequencing.
A UK-led international consortium is sequencing tuberculosis genomes and cataloguing drug resistance mutations to enable more rapid NGS-based diagnostics.
Genome.One's GoNavigate test will analyze the genetic risk for 49 disorders, as well as PGx variants related to more than 220 drugs.
Centogene said it will use the funds to accelerate growth and expansion in the areas of genetic testing, pharmaceutical collaborations, and big-data solutions.
Diagnostic decision support company Variantyx is betting that clinicians need help sorting through NGS data and that the trend is toward whole-genome sequencing.
The number of institutions offering clinical exome or genome tests to healthy individuals keeps increasing, but the practice remains controversial among medical experts.